long intergenic non-protein coding RNA 424Genealiases: []
Q-omics provides the consensus-scored LINC00424 profile across patient tissues and cancer cell-line models. LINC00424 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC00424 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, LINC00424 RNA expression shows 5,973 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight HNSC, KIRC, and STAD as cancer lineages where LINC00424 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00424 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00424 survival associations across molecular data types. LINC00424 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00424 RNA expression–survival associations across cancer types. High LINC00424 expression shows unfavorable associations in LIHC, UCEC, LUAD and BLCA, but favorable associations in HNSC and MESO. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC00424 RNA expression.
This table summarizes LINC00424 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00424. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00424 shows lower tumor expression in KIRC and BLCA. The KIRC box plot shows higher LINC00424 RNA expression in normal versus tumor tissue (log2 FC = −0.012, t-test p = .015).
This table shows molecular features associated with LINC00424 in patient tissues and cancer cell lines. In patient samples, LINC00424 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
